A miRNA-based signature predicts development of disease recurrence in HER2 positive early breast cancer after adjuvant trastuzumab-based treatment. A role for peripheral natural killer (NK) cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results